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Abstract—Cafestol, a diterpene present in unfiltered coffee, potently increases serum cholesterol levels in humans. So far,
no suitable animal model has been found to study the biochemical background of this effect. We determined the effect
of cafestol on serum cholesterol and triglycerides in different mouse strains and subsequently studied its mechanism of
action in apolipoprotein (apo) E*3-Leiden transgenic mice. ApoE*3-Leiden, heterozygous low density lipoprotein–
receptor (LDLR1/2) knockout, or wild-type (WT) C57BL/6 mice were fed a high- (0.05% wt/wt) or a low- (0.01%
wt/wt) cafestol diet or a placebo diet for 8 weeks. Standardized to energy intake, these amounts are equal to 40, 8, or
0 cups of unfiltered coffee per 10 MJ per day in humans. In apoE*3-Leiden mice, serum cholesterol was statistically
significantly increased by 33% on the low- and by 61% on the high-cafestol diet. In LDLR1/2 and WT mice, the
increases were 20% and 24%, respectively, on the low-cafestol diet and 55% and 46%, respectively, on the high-cafestol
diet. These increases were mainly due to a rise in very low density lipoprotein (VLDL) and intermediate density
lipoprotein cholesterol in all 3 mouse strains. To investigate the mechanism of this effect, apoE*3-Leiden mice were fed
a high-cafestol or a placebo diet for 3 weeks. Cafestol suppressed enzyme activity and mRNA levels of cholesterol
7a-hydroxylase by 57% and 58%, respectively. mRNA levels of enzymes involved in the alternate pathway of bile acid
synthesis, ie, sterol 27-hydroxylase and oxysterol 7a-hydroxylase, were reduced by 32% and 48%, respectively. The
total fecal bile acid output was decreased by 41%. Cafestol did not affect hepatic free and esterified cholesterol, but it
decreased LDLR mRNA levels by 37%. The VLDL apoB and triglyceride production rates, as measured after Triton
injection, were 2-fold decreased by cafestol, indicating that the number of particles secreted had declined and that there
was no change in the amount of triglycerides present in the VLDL particle during cafestol treatment. However, the
VLDL particles contained a 4-times higher amount of cholesteryl esters, resulting in a net 2-fold increased secretion of
cholesteryl esters. The decrease in triglyceride production was the result of a reduction in hepatic triglyceride content
by 52%. In conclusion, cafestol increases serum cholesterol levels in apoE*3-Leiden mice by suppression of the major
regulatory enzymes in the bile acid synthesis pathways, leading to decreased LDLR mRNA levels and increased
secretion of hepatic cholesterol esters. We suggest that suppression of bile acid synthesis may provide an explanation
for the cholesterol-raising effect of cafestol in humans. (Arterioscler Thromb Vasc Biol. 2000;20:1551-1556.)
Key Words: bile acid synthesis n cholesterol 7a-hydroxylase n sterol 27-hydroxylase
n apolipoprotein E*3-Leiden mice n cafestol
Unfiltered coffee markedly increases serum cholesterollevels in humans. The compounds responsible for this
effect are cafestol and kahweol, 2 diterpenes that are present
in coffee beans.1 From our experiments, cafestol appeared to
be by far the more potent compound.2 We estimated that each
10 mg of cafestol ingested per day raises serum cholesterol
levels by 0.13 mmol/L.3 In humans, ’80% of the rise in total
cholesterol is accounted for by LDL cholesterol, and the rest
is due to a rise in VLDL cholesterol.4
The mechanism by which coffee diterpenes influence lipid
metabolism is largely unknown. Recently, we reported that
cafestol suppressed bile acid synthesis in cultured rat hepa-
tocytes by downregulation of cholesterol 7a-hydroxylase and
sterol 27-hydroxylase.5 Suppression of bile acid synthesis
will lead to an increased pool of regulatory cholesterol,
resulting in decreased expression of the hepatic LDL receptor
(LDLR). This may provide an explanation for the cholester-
ol-raising effect of cafestol in humans.5 The availability of an
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animal model to study this hypothesis in vivo would be of
great value, since it may help us to validate our in vitro
experiments and eventually to discover the metabolic control
points of cafestol. However, in previous studies, various
animal models like hamsters6–8; rats6,9; gerbils8; and Cebus,
Rhesus, and African green monkeys10 did not respond to
cafestol and kahweol as humans do, regardless of the dosage,
the mode of administration, or the duration of treatment.
Therefore, we studied the effects of cafestol and kahweol
on serum lipoproteins in apolipoprotein E*3-Leiden (apoE*3-
Leiden) transgenic mice, in heterozygous LDLR-deficient
(LDLR1/2) mice, and in wild-type (WT) C57BL/6 mice.
We chose to use transgenic mice that overexpress human
apoE*3-Leiden because these mice are highly susceptible to
diet-induced hyperlipoproteinemia primarily due to a partial
defect in the hepatic uptake of remnant lipoproteins.11,12
Because it was anticipated from our studies in cultured rat
hepatocytes that cafestol would have an indirect effect on the
expression of the LDLR,5 experiments were also performed
with LDLR1/2 mice. Lipoprotein profiles from LDLR1/2
mice are more similar to those in humans than are those from
WT mice.13 The cholesterol-raising effect of cafestol ap-
peared to be most pronounced in apoE*3-Leiden mice,
allowing us to investigate the mechanism of the cholesterol-
raising effect of cafestol in these mice.
Methods
Animals, Housing, and Diets
Twenty-four female apoE*3-Leiden, 24 female LDLR1/2, and 24
female WT C57BL/6 mice were kept on a 12-hour dark/light cycle
and allowed free access to food and water. Mice were fed a common
challenge diet enriched with saturated fat and cholesterol (18.2
MJ/kg) containing (per 100 g) the following ingredients: cacao butter
15 g, corn oil 1 g, cholesterol 0.25 g, sucrose 40.5 g, corn starch 10 g,
cellulose 5.9 g, casein 20 g, minerals 5.1 g, choline chloride 1 g, and
methionine 0.2 g (Hope Farms). This diet was supplemented with
0.05% (wt/wt) cafestol and 0.025% (wt/wt) kahweol (high-cafestol
diet), 0.01% (wt/wt) cafestol and 0.005% (wt/wt) kahweol (low-
cafestol diet), or placebo. Standardized to daily energy intake, these
amounts are comparable to a daily consumption of 40, 8, or 0 cups
of unfiltered coffee, respectively, per 10 MJ (the average daily
energy intake in humans). Institutional guidelines for animal care
were observed in all experiments.
Experimental Design
Per mouse strain, animals were randomly divided into 3 experimen-
tal groups of 8 mice each and were matched by age. During a run-in
period of 4 weeks, all mice received the placebo diet. During the
treatment period, the groups consumed either the high- or low-
cafestol diet or the placebo diet. Blood was collected at weeks 0, 2,
4, and 8 of the treatment period after an overnight fasting period.
After 8 weeks of treatment, mice were bled and killed.
Measurement of Serum Lipids and Lipoproteins
In serum, total cholesterol and triglycerides were measured enzy-
matically (CHOD-PAP method, Boehringer Mannheim No. 236691,
and GPO-trinder, Sigma No. 337-B, respectively). Alanine amino-
transferase was measured enzymatically (GPT, Boehringer Mann-
heim No. 745138) in pooled sera from 4 mice. Serum lipoproteins
were separated by ultracentrifugation. Two hundred microliters of
pooled sera per group was layered with 1 mL of KBr (r51.21), 2.58
mL of NaCl (r51.063), and 8 mL of distilled water and centrifuged
for 18 hours at 40 000 rpm at 4°C in a Beckman SW41 rotor. After
fraction collection, cholesterol was measured enzymatically.
Enzyme Activity of Cholesterol 7a-Hydroxylase
and Sterol 27-Hydroxylase and Measurement of
Liver Lipids
In livers from mice fed the high-cafestol or placebo diet for 3 weeks,
enzyme activities of cholesterol 7a-hydroxylase in microsomes and
of sterol 27-hydroxylase in mitochondria were determined as de-
scribed previously14 by measuring the mass conversion of cholester-
ol into 7a- and 27-hydroxycholesterol. Liver lipids were measured as
described.14
RNA Isolation, Blotting, and
Hybridization Procedures
Isolation of total RNA and subsequent electrophoresis, Northern
blotting, probe, and hybridization techniques were performed as
described previously.5,15–17 The GAPDH mRNA or 18S rRNA was
used as an internal standard to correct for differences in the amount
of total RNA applied onto the gel. mRNA levels were quantified as
described previously.14
Fecal Sterol Analysis
Feces were sampled for 3 days continuously in weeks 3 and 6 of the
experimental period. Aliquots of lyophilized feces were used for
determination of neutral and acidic sterol contents by gas-liquid
chromatography procedures described previously.18,19
In Vivo Hepatic VLDL Production in
ApoE*3-Leiden Mice
Mice that were fed the high-cafestol or placebo diet for 3 weeks were
fasted for 4 hours (from 8 AM to 12 noon) and then injected in the tail
vein with 0.1 mL of PBS containing 100 mCi of Tran35S label (ICN)
to measure de novo apoB synthesis. After 30 minutes, Triton
WR1339 (500 mg/kg body weight) was injected into the tail vein.
Triton virtually completely inhibits serum VLDL clearance.20 Serum
triglycerides were determined before injection (t50 minutes) and at
different time points after injection. The hepatic VLDL triglyceride
production rate was calculated from the slope of the curve. Serum
collected 180 minutes after Triton injection was pooled, and VLDL
was subsequently isolated by ultracentrifugation in triplicate. Tri-
glycerides, total and free cholesterol, and phospholipids were mea-
sured enzymatically as described previously.12 Cholesteryl esters
were calculated as the difference between total and free cholesterol.
35S-labeled apoB was precipitated by incubating 1.2 mL of the
isolated VLDL fraction together with 0.1 mL of human LDL (100
mg) as the carrier and 0.5 mL of isopropanol for 1 hour at room
temperature and centrifuged for 10 minutes at 13 000 rpm in an
Eppendorf centrifuge. The pellet was dissolved in 20% (wt/vol) SDS
for 15 minutes at 60°C, and radioactivity was subsequently deter-
mined. To determine the apoB content of the VLDL particle, VLDL
protein was subjected to 4% to 20% SDS–polyacrylamide gel
electrophoresis, and the contribution of apoB to total protein was
calculated.
Statistical Analyses
We calculated the change in serum lipids per mouse by subtracting
values at the start of the experimental period from values obtained
during the experimental period. After checking for normality, dif-
ferences in changes between treatment groups and the control group
were tested by using the 1-tailed, Student’s unpaired t test. Other data
were analyzed statistically by using a 2-tailed, Student’s unpaired t
test with the level of significance selected at P,0.05. Values are
expressed as mean6SD.
Results
Food, Body Weight, and Alanine Aminotransferase
The initial body weight values (mean, 20.960.9 g) did not
differ between treatment groups, whereas the final body
weight values were significantly (P,0.05) lower in the
high-cafestol treatment group compared with the placebo
treatment group (21.060.2 versus 22.960.7 g). Average
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daily food intakes were significantly (P,0.05) lower (27%
and 215%, respectively) on the low-cafestol and high-
cafestol diets compared with placebo treatment (mean,
2.760.2 g/d). Concentrations of alanine aminotransferase did
not significantly increase during consumption of cafestol in
all mouse strains.
Cafestol Increases Serum Lipid and
Lipoprotein Levels
Cafestol raised serum cholesterol in all 3 mouse strains after
8 weeks of dietary intervention (Figure 1). In apoE*3-Leiden
mice, serum cholesterol was raised by 33% (3.46 mmol/L;
95% CI, 1.62 to 5.30) in the low-cafestol-diet group and by
61% (6.35 mmol/L; 95% CI, 4.47 to 8.22) in the high-
cafestol-diet group. In LDLR1/2 mice, serum cholesterol
was raised by 20% (0.85 mmol/L; 95% CI, 20.25 to 1.94) in
the low-cafestol-diet group and by 55% (2.37 mmol/L; 95%
CI, 0.73 to 4.01) in the high-cafestol-diet group. In WT mice,
serum cholesterol was raised by 24% (0.62 mmol/L; 95% CI,
0.34 to 0.90) in the low-cafestol-diet group and by 46%
(1.21 mmol/L; 95% CI, 0.92 to 1.21) in the high-cafestol-diet
group. The rise in serum cholesterol was predominantly due
to a rise in VLDL and IDL cholesterol (Figure 2). Serum
triglycerides were increased after 2 weeks in apoE*3-Leiden
and WT mice and remained significantly higher in the
apoE*3-Leiden mice during cafestol treatment compared
with placebo treatment (Figure 1). Because the effects on
serum cholesterol were most pronounced in the apoE*3-
Leiden mice, we investigated the mechanism of the choles-
terol-raising effect of cafestol in these mice.
Cafestol Decreases Hepatic Enzymes in Bile Acid
Synthesis and Fecal Excretion of Bile Acids
To validate the effects of cafestol on bile acid synthesis
obtained in cultured rat hepatocytes,5 we determined the
effect of a high-cafestol diet on enzymes involved in bile acid
synthesis and on fecal bile acid excretion in apoE*3-Leiden
mice. Cafestol decreased cholesterol 7a-hydroxylase activity
and mRNA levels by 57% and 58%, respectively (Table 1).
Cafestol also decreased sterol 27-hydroxylase mRNA levels
by 32%, while the enzyme activity was paradoxically in-
creased by 40% (Table 1). The oxysterol formed by sterol
27-hydroxylase can be further converted by oxysterol 7a-
hydroxylase, an important enzyme in the alternate pathway of
bile acid synthesis.21–23 We measured mRNA levels of
oxysterol 7a-hydroxylase to investigate whether cafestol had
other effects on the alternate pathway. The expression of this
enzyme was decreased by 58% (Table 1).
Figure 1. Effect of a high-cafestol (0.05%
wt/wt) diet (black symbols), a low-cafestol
(0.01% wt/wt) diet (gray symbols), and a
placebo (white symbols) diet on serum cho-
lesterol and triglycerides in apoE*3-Leiden
(circles), LDLR1/2 (squares), and WT (trian-
gles) mice. Significant differences between
the cafestol and placebo treatment are indi-
cated by an asterisk.
Figure 2. Effect of a high-cafestol (0.05% wt/wt) diet on choles-
terol profiles in apoE*3-Leiden, LDLR1/2, and WT mice. Cho-
lesterol profiles from pooled sera of 8 mice at the start of the
experimental period (t50, open symbols) and after 8 weeks
(closed symbols) of treatment with the high-cafestol diet.
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Because downregulation of enzymes involved in bile acid
synthesis has consequences for the overall process of bile
acid production, the amount of total and individual fecal bile
acids was measured. Cafestol decreased the total amount of
bile acids excreted in the feces by 41% (Table 2). Further-
more, the amount of fecal neutral sterols excreted after
cafestol treatment appeared to be slightly lower compared
with the placebo group (Table 2). These effects were similar
after 3 and 6 weeks on the high-cafestol or placebo diet.
Effect of Cafestol on VLDL Production and
Hepatic Lipid Metabolism
To investigate the effects of decreased bile acid synthesis on
hepatic lipid metabolism, we determined the amount of
hepatic lipids in apoE3*-Leiden mice treated with a high-
cafestol or placebo diet for 3 weeks. Cafestol significantly
(P,0.05) decreased the hepatic triglyceride content by 52%
(86.3610.6 versus 41.168.7 mg/mg protein), but it did not
alter the liver free and esterified cholesterol levels (data not
shown). Although the hepatic content of free cholesterol in
apoE*3-Leiden mice was apparently not affected by cafestol,
the putative regulatory pool of cholesterol was increased, as
indicated by a decreased expression of the LDLR (237%;
Table 1).
Because the excess hepatic cholesterol was not excreted
into the bile, it might have been secreted into VLDL particles.
Therefore, we measured nascent VLDL production in
apoE*3-Leiden mice after 3 weeks on a high-cafestol or
placebo diet. The VLDL apoB production was 2-fold de-
creased after cafestol treatment, indicative of a decline in
secretion of VLDL particles (Figure 3A). However, the
absolute number of cholesteryl esters in the VLDL particles
during cafestol treatment was 4 times higher compared with
placebo treatment (Table 3), indicative of the secretion of a
b-VLDL–like particle, and resulting in a net 2-fold increased
secretion of cholesteryl esters. The VLDL triglyceride pro-
duction rate decreased to the same extent as the decline in
apoB secretion (35.1613.8 after cafestol treatment versus
63.1617.5 mmol z h21 z kg21 after placebo treatment; Figure
3B). Therefore, we did not observe a significant change in the
absolute amount of triglycerides in nascent VLDL.
Discussion
In this study, cafestol increased serum cholesterol levels in
apoE*3-Leiden, LDLR1/2, and WT mice, mainly in the
VLDL and IDL fractions. In apoE*3-Leiden mice, cafestol
decreased bile acid synthesis, as reflected by a reduction in
the total amount of fecal bile acids, by downregulating the
expression of enzymes involved in the neutral as well as in
the alternate bile acid synthetic pathway. The decrease in bile
acid synthesis resulted in a decline in LDLR mRNA levels
and an increased secretion of VLDL cholesterol ester.
In contrast to other animal models,6–10 these mice are the
first animals to show an increase in serum cholesterol due to
cafestol that is similar to what has been observed in humans,
making the mouse a good model to investigate the biochem-
ical background of the cholesterol-raising effect of cafestol in
humans. It should be noted that the increase in serum
TABLE 1. Effect of Cafestol on Hepatic mRNA and Activity Levels in
ApoE*3-Leiden Mice
Placebo Diet, % of Placebo
High-Cafestol Diet, % of
Placebo
Activity mRNA Activity mRNA
Cholesterol 7a-hydroxylase 10065 100641 4361* 4267*
Sterol 27-hydroxylase 100610 100612 14065* 68617*
Oxysterol 7a-hydroxylase ND 100621 ND 41616†
LDLR ND 100626 ND 63614*
ND indicates not determined. Hepatic enzyme activities and mRNA levels of apoE*3-Leiden mice
treated for 3 weeks with a high-cafestol (0.05% wt/wt) or placebo diet were determined after a
4-hour fasting period from 8 AM until 12 noon. Absolute activities of cholesterol 7a-hydroxylase and
sterol 27-hydroxylase from mice treated the placebo diet were 1.83 and 1.76 nmol z h21 z mg protein,
respectively. Data shown are mean6SD (n54 per group). A significant difference is indicated
(*P,0.05, †P,0.005).
TABLE 2. Effects of Cafestol on Fecal Bile Acid Excretion and Composition and on Excretion of Neutral Sterols From
ApoE*3-Leiden Mice
Treatment
Bile Acid Excretion,
mmol z d21 z 100
g21 Body Weight DC C LC CDC HDC UDC a/bMC vMC
Neutral Sterol Excretion,
mmol z d21 z 100
g21 Body Weight
Placebo diet 6.860.7 21 15 4 1 2 3 28 26 34.361.3
(100%) (100%)
High-cafestol diet 4.060.1 30 13 3 1 2 3 16 32 27.962.8
(59%) (81%)
DC indicates deoxycholate; C, cholate; LC, lithocholate; CDC, chenodeoxycholate; HDC, hyodeoxycholate; UDC, ursodeoxycholate; and MC, muricholate. Mice were
treated with a high-cafestol diet or a placebo diet for 3 weeks. In feces, total bile acids, neutral sterols, and bile acid composition were determined as described in
Methods. Data are mean6range of 2 individual feces samples of each group in percent. Values in parentheses represent percentages of the value obtained in animals
treated with the placebo diet.
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cholesterol in humans is mainly present in LDL, whereas in
mice, the rise was found predominantly in the VLDL-IDL
range. Differences in the absorption and/or metabolism of
coffee diterpenes, or in their effects on lipoprotein metabo-
lism, may underlie the absence of a response in a range of
other animal species.
Previously, we reported that cafestol suppressed bile acid
synthesis by downregulation of cholesterol 7a-hydroxylase
and sterol 27-hydroxylase expression in rat hepatocytes.5 This
concept is now confirmed in vivo in apoE*3-Leiden mice.
Cafestol suppressed bile acid synthesis by downregulation of
cholesterol 7a-hydroxylase, sterol 27-hydroxylase, and oxys-
terol 7a-hydroxylase expression, indicative of inhibition of
both the acidic and the neutral pathways in bile acid synthe-
sis. Whereas cafestol decreased mRNA levels of sterol
27-hydroxylase, its enzyme activity was paradoxically in-
creased. An explanation for this apparent discrepancy would
be that the enzyme oxysterol 7a-hydroxylase is present in the
mitochondrial fractions of these mice and converts 27-
hydroxycholesterol into 7a,27-dihydroxycholesterol.21–23 In-
deed, we found decreased expression of oxysterol 7a-
hydroxylase mRNA and that its expression is inhibited by
cafestol. Thus, it is possible that the apparent increase in
sterol 27-hydroxylase activity can be attributed to accumula-
tion of its product, 27-hydroxycholesterol, caused by a
blockade in the subsequent metabolic conversion involving
oxysterol 7a-hydroxylase. Concomitant with the reduction in
fecal bile acids, fecal excretion of neutral sterols tended to be
lowered. However, because food intake in the cafestol-treated
animals was slightly reduced, leading to a lesser intake of
dietary cholesterol, the data on neutral sterol excretion may
be an underestimate.
Theoretically, suppressed bile acid synthesis would in-
crease the hepatic pool of free cholesterol. We did not find an
effect on hepatic free cholesterol levels, but different meta-
bolic pathways might have converted the free cholesterol into
cholesteryl esters or removed it from the liver as such and/or
via VLDL particles to maintain hepatic cholesterol homeosta-
sis. Because we did not find a hepatic accumulation of
cholesteryl esters, it appears plausible that the cholesterol that
becomes available due to inhibition of bile acid synthesis is
directly removed from the liver via VLDL particles (see
below). In addition, high amounts of free cholesterol in cell
membranes24 may overshadow the subtle changes in free
cholesterol caused by inhibition of bile acid synthesis. We
found a substantial decrease in LDLR mRNA, which is a
sensitive measure to detect changes in the putative regulatory
pool of free cholesterol. Subtle increases in intracellular
cholesterol prevent processing of the sterol regulatory el-
ement–binding protein, resulting in downregulation of LDLR
gene transcription.25 A similar decrease in LDLR mRNA
levels has been shown in vitro in cultured rat hepatocytes5
and in HepG2 cells.26 In contrast, divergent data were
reported in other cell types,27,28 possibly because of different
metabolic functions of these cells. Our results plead in favor
of the hypothesis that the cholesterol-raising effect of cafestol
can be explained by a reduced expression of the LDLR.
The rise in serum cholesterol during cafestol treatment may
also be partly explained by an increased secretion of cho-
lesteryl esters in VLDL. Despite the 2-fold reduction in
VLDL particles, the 4-fold increase in the absolute amount of
cholesteryl esters in VLDL particles, leading to a net 2-fold-
enhanced secretion of cholesteryl esters during cafestol treat-
ment, also contributed to the increase in plasma cholesterol
levels after cafestol treatment. Concomitantly, the absolute
amount of triglycerides in the particles did not change
significantly. This was the result of a similar reduction in the
VLDL triglyceride secretion rate and the secretion of VLDL
particles. The decrease in VLDL triglyceride production rate
and the reduced hepatic triglyceride content suggest impaired
triglyceride synthesis. Whether this is due to a direct or
indirect effect of cafestol on the activity or expression of the
enzymes involved in triglyceride synthesis awaits further
investigation.
Figure 3. Effect of cafestol on VLDL production in apoE*3-
Leiden mice. Tran35S label (100 mCi) was injected into placebo-
and cafestol- (0.05% wt/wt) treated apoE*3-Leiden mice (n58
fasted mice per group). After 30 minutes Triton WR1339 (500
mg/kg body weight) was injected, and serum samples were
taken at different time points. VLDL was isolated by ultracentrif-
ugation from pooled sera collected 180 minutes after Triton
injection. 35S-labeled apoB was precipitated from the VLDL frac-
tion, and radioactivity was subsequently measured (A). Serum
triglyceride levels were determined at indicated time points and
corrected for the triglyceride level at the time of injection. The
values shown are mean6SD of 4 individual VLDL samples of
each group (A) or mean6SD of serum samples of 8 mice (B). A
significant difference between placebo- (open symbols) and
cafestol- (closed symbols) treated mice is indicated by an aster-
isk (P,0.05).
TABLE 3. Effect of Cafestol on VLDL Composition in ApoE*3-Leiden Mice
Treatment Triglycerides Free Cholesterol Cholesteryl Ester Phospholipids
Placebo 26.566.0 8.760.9 11.863.8 12.462.2
Cafestol 18.863.0 9.961.2 48.1623.7* 11.461.5
VLDL was isolated from the pooled sera of 8 fasted mice treated with a high-cafestol or a placebo
diet. The serum was collected 180 minutes after Triton injection. Triglycerides, total cholesterol, free
cholesterol, and phospholipids were measured enzymatically, and the amount of cholesteryl ester
was calculated (see Methods). Apo B was also measured as indicated in Methods. Data are
mean6SD of 3 individual VLDL samples from each group and are in mmol/mg of apo B. A significant
difference is indicated *P,0.05.
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In conclusion, we found that cafestol inhibits bile acid
synthesis by downregulation of both the neutral and the acidic
pathway, leading to a decrease in expression of the LDLR and
an elevated secretion of cholesteryl esters in VLDL. Suppres-
sion of bile acid synthesis may provide an explanation for the
cholesterol-raising effects of unfiltered coffee in humans.
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